Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
Labcorp (NYSE: LH) announced it will offer the Elecsys® pTau-217 blood test, the first FDA-cleared single-biomarker test to detect Alzheimer's disease pathology. Developed by Roche Diagnostics, the test measures phosphorylated Tau 217, an indicator of amyloid pathology, in individuals 55 and older with cognitive decline symptoms. The test will be available nationwide in primary and specialty care settings, providing a standardized approach to patient assessment. Labcorp plans to make the test av
How this was made
The 30-second read
Why it matters
The test offers a less invasive, standardized alternative to CSF and PET imaging, potentially increasing test volume for Labcorp's 2,200 service centers.
Market read
First FDA‑cleared single‑biomarker blood test for Alzheimer’s could create a new revenue stream and influence diagnostics market dynamics.
What to watch
Competition from other pTau assays and the need for physician adoption could temper growth.
Background
Labcorp announced the FDA clearance of its Elecsys® pTau-217 test, developed with Roche Diagnostics, targeting patients 55+ with cognitive decline.
Ticker impact
Labcorp received FDA clearance for its Elecsys® pTau-217 blood test, the first single‑biomarker test to rule in and out amyloid pathology.
potential modest upside as the test rolls out nationwide
Large‑cap lab services firm adding a first‑of‑its‑kind FDA‑cleared test is a material product launch.
Market effects
May boost the broader diagnostics and neuro‑degenerative disease testing sector.
U.S. healthcare and biotech markets could see modest interest.
Sets a precedent for blood‑based Alzheimer’s diagnostics worldwide.
Counterpoint
Revenue impact may be limited if insurers are slow to reimburse the new test.
Key entities
- CompanyLabcorp
Global laboratory services provider (NYSE: LH).
- CompanyRoche Diagnostics
Developer of the Elecsys® pTau-217 assay.
